Powerful new option for treating vasculitis News-Medical.net Among patients receiving rituximab, 64 percent were in remission at six months, 48 percent at one year and 39 percent at 18 months, compared to 53 percent, 39 percent and 33 percent for standard therapy. "The FDA approved rituximab for vasculitis based ... UAB Part of Study of New Drug for Vasculitis |
